Option chain shows key data for FTAI Aviation's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for FTAI Aviation.

FTAI Aviation (NASDAQ:FTAIN) Stock, Option Chain

FTAI Aviation

FTAI Aviation Ltd is a aerospace company .It owns and maintains commercial jet engines with a focus on CFM56 engines. FTAI owns and leases jet aircraft which often facilitates the acquisition of engines at attractive prices. It invests in aviation assets and aerospace products that generate strong and stable cash flows with the potential for earnings growth and asset appreciation.

FTAI Aviation Ltd. - 8.25% Fixed-Rate Reset Series C Cumulative Perpetual Redeemable Preferred Shares

FTAI Aviation Ltd

News

Guidance

OTLY

Oatly Sees FY25 Constant Currency Revenue Growth Of 2% - 4%

Financing

ALGS

Aligos Therapeutics Announces $105M Private Placement Financing; Proceeds Expected To Fund The Start Of Its ALG-000184 Phase 2 Study

Urban Edge Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UE#NYSE">UE</a>) reported quarterly earnings of $0.34 per share which met the analyst consensus estimate. This is a 9.68 percent increase over earnings of $0.31 per share from the same period last year. The company reported quarterly sales of $116.37 million which beat the analyst consensus estimate of $110.79 million by 5.03 percent. This is a 0.18 percent decrease over sales of $116.58 million the same period last year.

Earnings

Earnings Beats

Urban Edge Props Q4 FFO $0.34, Inline, Sales $116.37M Beat $110.79M Estimate

Kraft Heinz (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KHC#NASDAQ">KHC</a>) reported quarterly earnings of $0.84 per share which beat the analyst consensus estimate of $0.78 by 7.69 percent. This is a 7.69 percent increase over earnings of $0.78 per share from the same period last year. The company reported quarterly sales of $6.58 billion which missed the analyst consensus estimate of $6.66 billion by 1.32 percent. This is a 4.14 percent decrease over sales of $6.86 billion the same period last year.

Earnings Misses

Kraft Heinz Q4 Adj EPS $0.84 Beats $0.78 Estimate, Sales $6.58B Miss $6.66B Estimate

Kraft Heinz Sees FY25 Adj. EPS $2.63-$2.74 Vs $3.04 Estimate

The company confirmed that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act has expired and that it has received early termination of the waiting period from the Canadian Competition Bureau.

BECN

QXO Obtains Antitrust Clearance In Both US And Canada For Its Acquisition Of Beacon Roofing Supply

Alkermes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALKS#NASDAQ">ALKS</a>) reported quarterly earnings of $1.04 per share which beat the analyst consensus estimate of $0.79 by 31.65 percent. This is a 116.67 percent increase over earnings of $0.48 per share from the same period last year. The company reported quarterly sales of $429.99 million which beat the analyst consensus estimate of $379.74 million by 13.23 percent. This is a 13.91 percent increase over sales of $377.48 million the same period last year.

ALKS

Alkermes Q4 2024 Adj EPS $1.04 Beats $0.79 Estimate, Sales $429.99M Beat $379.74M Estimate

PolyPid (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPD#NASDAQ">PYPD</a>) reported quarterly losses of $(1.13) per share which missed the analyst consensus estimate of $(0.82) by 37.8 percent. This is a 71.54 percent increase over losses of $(3.97) per share from the same period last year.

PYPD

PolyPid Q4 2024 GAAP EPS $(1.13) Misses $(0.82) Estimate; Cash $15.6M

Healthcare Services Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCSG#NASDAQ">HCSG</a>) reported quarterly earnings of $0.16 per share which missed the analyst consensus estimate of $0.20 by 20 percent. The company reported quarterly sales of $437.800 million which beat the analyst consensus estimate of $434.044 million by 0.87 percent. This is a 3.29 percent increase over sales of $423.840 million the same period last year.

HCSG

Healthcare Services Group Q4 2024 GAAP EPS $0.16 Misses $0.20 Estimate, Sales $437.800M Beat $434.044M Estimate

MDWD

MediWound Initiates VALUE Global Phase III Trial Of EscharEx In Treatment Of Venous Leg Ulcers

Barclays analyst Gena Wang maintains CRISPR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>) with a Equal-Weight and raises the price target from $55 to $56.

Price Target

Analyst Ratings

CRSP

Barclays Maintains Equal-Weight on CRISPR Therapeutics, Raises Price Target to $56

Oatly Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTLY#NASDAQ">OTLY</a>) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.07) by 114.29 percent. This is a 70 percent increase over losses of $(0.50) per share from the same period last year. The company reported quarterly sales of $214.32 million which missed the analyst consensus estimate of $217.80 million by 1.60 percent. This is a 4.99 percent increase over sales of $204.12 million the same period last year.

Oatly Group Q4 EPS $(0.15) Misses $(0.07) Estimate, Sales $214.32M Miss $217.80M Estimate

Alkermes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALKS#NASDAQ">ALKS</a>) reported quarterly earnings of $2.92 per share which beat the analyst consensus estimate of $2.66 by 9.77 percent. This is a 24.79 percent increase over earnings of $2.34 per share from the same period last year. The company reported quarterly sales of $1.56 billion which beat the analyst consensus estimate of $1.51 billion by 3.32 percent. This is a 93.66B percent increase over sales of $1.66 the same period last year.

Alkermes FY 2024 Adj EPS $2.92 Beats $2.66 Estimate, Sales $1.56B Beat $1.51B Estimate

NiSource (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NI#NYSE">NI</a>) raises FY2025 Adj EPS guidance from $1.84-$1.88 to $1.85-$1.89 vs $1.86 analyst estimate..

NiSource Raises FY2025 Adj EPS Guidance from $1.84-$1.88 to $1.85-$1.89 vs $1.86 Est

NiSource (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NI#NYSE">NI</a>) reported quarterly earnings of $0.49 per share which missed the analyst consensus estimate of $0.50 by 2 percent. This is a 7.55 percent decrease over earnings of $0.53 per share from the same period last year. The company reported quarterly sales of $1.59 billion which beat the analyst consensus estimate of $1.54 billion by 3.04 percent. This is a 11.67 percent increase over sales of $1.42 billion the same period last year.

NiSource Q4 Adj $0.49 Misses $0.50 Estimate, Sales $1.59B Beat $1.54B Estimate

Mineralys Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLYS#NASDAQ">MLYS</a>) reported quarterly losses of $(0.98) per share which beat the analyst consensus estimate of $(1.04) by 5.77 percent. This is a 60.66 percent decrease over losses of $(0.61) per share from the same period last year.

MLYS

Mineralys Therapeutics Q4 EPS $(0.98) Beats $(1.04) Estimate

Barclays analyst Jiong Shao maintains Coupang (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPNG#NYSE">CPNG</a>) with a Overweight and raises the price target from $32 to $34.

CPNG

Barclays Maintains Overweight on Coupang, Raises Price Target to $34

Interpublic Gr of Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IPG#NYSE">IPG</a>) reported quarterly earnings of $1.11 per share which missed the analyst consensus estimate of $1.17 by 5.13 percent. This is a 5.93 percent decrease over earnings of $1.18 per share from the same period last year. The company reported quarterly sales of $2.434 billion which missed the analyst consensus estimate of $2.518 billion by 3.35 percent. This is a 5.88 percent decrease over sales of $2.586 billion the same period last year.

Interpublic Gr of Cos Q4 2024 Adj. EPS $1.11 Misses $1.17 Estimate, Sales $2.434B Miss $2.518B Estimate

CME Gr Q4 2024 Adj. EPS $2.52 Beats $2.44 Estimate, Sales $1.525B Beat $1.519B Estimate

The Chefs' Warehouse (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHEF#NASDAQ">CHEF</a>) reported quarterly earnings of $0.55 per share which beat the analyst consensus estimate of $0.51 by 7.84 percent. This is a 17.02 percent increase over earnings of $0.47 per share from the same period last year. The company reported quarterly sales of $1.033 billion which beat the analyst consensus estimate of $1.003 billion by 2.97 percent. This is a 8.68 percent increase over sales of $950.473 million the same period last year.

Comments

FTAI Aviation

FTAI Aviation (FTAIN) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga